期刊
LEUKEMIA & LYMPHOMA
卷 48, 期 5, 页码 885-891出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190701223275
关键词
lymphoproliferative disorder; Epstein-Barr virus; liver transplantation; PTLD; posttransplant lymphoma
资金
- NHLBI NIH HHS [T32 HL007775] Funding Source: Medline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007775] Funding Source: NIH RePORTER
Posttransplant lymphoproliferative disorder ( PTLD) is a major complication of liver transplantation, but previous descriptions have been limited to case reports and small case series. We report a retrospective analysis of 17 consecutive cases of PTLD associated with liver transplantation. The median age at PTLD diagnosis was 47 years ( range 19-63) with a median time of 25 months from liver transplantation to PTLD diagnosis ( range 3-75). PTLD location was frequently extranodal ( 71%) and involved the transplanted liver ( 41%). PTLD histology consisted of nine ( 53%) monomorphic and eight ( 47%) polymorphic disease. EBV was present by in situ hybridization in 11 ( 79%) of 14 cases evaluated. Initial therapy included reduction in immunosuppression ( RI) alone in 13 ( 76%) of 17 patients, resulting in 6 ( 46%) complete responses ( CR) and 7 ( 54%) progressive disease ( PD). Monoclonal CD20 antibody ( rituximab) and CHOP chemotherapy were used as initial therapy or as second line after RI failure. Currently, five patients ( 29%) are alive in CR. Although detection and treatment of PTLD in liver transplant recipients remains problematic and upfront mortality is still high, long-term survival is possible. Further studies are necessary to better define treatment strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据